Trial · NCT02088216
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Number of Exacerbations | 12 months | An exacerbation of bronchiectasis is defined as either a change in one or more of the common symptoms of bronchiectasis (sputum volume or purulence, dyspnea, cough, and fatigue/malaise) or the onset of new symptoms (fever, pleurisy, haemoptysis or need for antibiotic treatment). |
| Secondary | Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up. | 12 months | The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. |
| Secondary | Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa | 12 months | The values in the table were calculated as the value at baseline minus the value at 12 months. |
| Secondary | Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines | 12 months | Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores: the minimum value is 0 and the maximum value is 40. 0-10 points: "slight impact"; 11-20 points: "medium impact"; 21-30 points: "serious impact"; 31-40 points: "very serious impact". The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. |
| Secondary | Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines | 12 months | The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. |
| Secondary | Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines | 12 months | The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. |
| Secondary | Change of Forced Vital Capacity (FVC) From Baselines | 12 months | The change was calculated from two time points as the value at the later time point minus the value at the earlier time point. |
| Secondary | Time to the First Exacerbation | 12 months | |
| Secondary | Time to Recurrent Exacerbations | 12 months | |
| Secondary | Nature of Sputum (Number of Patients With Yellow Purulent) | 12 months | |
| Secondary | Adverse Events (AEs) (Elevation of Liver Enzymes) | 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02088216/registered